The 36-month beta value for AKRO is also noteworthy at -0.12. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AKRO is 70.71M, and at present, short sellers hold a 8.92% of that float. The average trading volume of AKRO on May 01, 2025 was 1.11M shares.
AKRO) stock’s latest price update
Akero Therapeutics Inc (NASDAQ: AKRO) has seen a rise in its stock price by 5.97 in relation to its previous close of 43.04. However, the company has experienced a 15.15% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-30 that SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two oral presentations and an upcoming poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, 2025, in Amsterdam, the Netherlands.
AKRO’s Market Performance
Akero Therapeutics Inc (AKRO) has seen a 15.15% rise in stock performance for the week, with a 12.67% gain in the past month and a -15.54% plunge in the past quarter. The volatility ratio for the week is 4.97%, and the volatility levels for the past 30 days are at 7.38% for AKRO. The simple moving average for the past 20 days is 17.57% for AKRO’s stock, with a 35.02% simple moving average for the past 200 days.
Analysts’ Opinion of AKRO
Many brokerage firms have already submitted their reports for AKRO stocks, with BofA Securities repeating the rating for AKRO by listing it as a “Buy.” The predicted price for AKRO in the upcoming period, according to BofA Securities is $63 based on the research report published on January 30, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKRO reach a price target of $72, previously predicting the price at $50. The rating they have provided for AKRO stocks is “Buy” according to the report published on January 27th, 2025.
Citigroup gave a rating of “Buy” to AKRO, setting the target price at $65 in the report published on November 18th of the previous year.
AKRO Trading at 6.87% from the 50-Day Moving Average
After a stumble in the market that brought AKRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.90% of loss for the given period.
Volatility was left at 7.38%, however, over the last 30 days, the volatility rate increased by 4.97%, as shares surge +18.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.75% lower at present.
During the last 5 trading sessions, AKRO rose by +15.15%, which changed the moving average for the period of 200-days by +77.61% in comparison to the 20-day moving average, which settled at $38.79. In addition, Akero Therapeutics Inc saw 63.95% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKRO starting from Rolph Timothy, who sale 6,250 shares at the price of $41.03 back on Apr 24 ’25. After this action, Rolph Timothy now owns 169,721 shares of Akero Therapeutics Inc, valued at $256,438 using the latest closing price.
Yale Catriona, the Chief Development Officer of Akero Therapeutics Inc, sale 9,073 shares at $37.91 during a trade that took place back on Apr 15 ’25, which means that Yale Catriona is holding 95,034 shares at $343,962 based on the most recent closing price.
Stock Fundamentals for AKRO
The total capital return value is set at -0.36. Equity return is now at value -39.22, with -35.85 for asset returns.
Based on Akero Therapeutics Inc (AKRO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.31. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -61.14.
Currently, EBITDA for the company is -285.42 million with net debt to EBITDA at 1.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.38.
Conclusion
In summary, Akero Therapeutics Inc (AKRO) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
